Olezarsen

Phase 3

Ionis Pharmaceuticals, Inc. (IONS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

IONSPhase 3$12.2B

Olezarsen Phase 3 Est. Readout

Olezarsen• Familial Chylomicronemia Syndrome24

Jun 2027~ConfirmedSTALE

CT.gov

00%

Mar '27

IONSPhase 3$12.2B

Olezarsen Phase 3 Est. Readout

Olezarsen• Familial Chylomicronemia Syndrome885

Mar 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

2 competitors in Familial Chylomicronemia Syndrome

View Full Landscape

Drug Information

Target Indication

Familial Chylomicronemia Syndrome

Clinical Trial

NCT04568434

Last updated: 12/4/2025

Patent & Exclusivity

ActiveRLD

Latest Patent Expiry

May 1, 2034(7y 8m)

Patents Listed

Exclusivity

NSI-992ODE-515

Application

NDA 218614

Source: FDA Orange Book

Regulatory Approvals

EMA9/17/2025

Tryngolza

Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ION582Phase 3

Angelman Syndrome

ION363Phase 3

Amyotrophic Lateral Sclerosis

VolanesorsenPhase 3

Familial Chylomicronemia Syndrome

InotersenPhase 3

FAP

zilganersenPhase 3

Alexander Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts